U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07167966) titled 'Alzheimer's Tau Platform: Regimen A - AADvac1' on Aug. 27.
Brief Summary: The Alzheimer's Tau Platform (ATP) is a multi-center platform trial to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with an anti-amyloid monoclonal antibody (mAb), in adults aged 50-80 with late preclinical or early prodromal Alzheimer's disease.
Regimen A will evaluate the safety and efficacy of AADvac1, alone or in combination with an anti-amyloid mAb.
Study Start Date: Nov., 2025
Study Type: INTERVENTIONAL
Condition:
Preclinical Alzheimer's Disease
Prodromal Alzheimer's Disease
Alzheimer Disease
Interventio...